Αρχική World News Hypogammaglobulinemia and Sars-CoV-2 Viraemia Determine COVID-19 Severity in Patients with Haematological Malignancies

Hypogammaglobulinemia and Sars-CoV-2 Viraemia Determine COVID-19 Severity in Patients with Haematological Malignancies

Dr Jean-Marie Michot and colleagues from the Gustave Roussy in Villejuif, France investigated clinical factors associated with higher risk for severe COVID-19 in patients with haematological malignancies. They wrote on 12 July 2021 in the Annals of Oncology that the coronavirus infection itself, rather than cytokine storm, lead to severe and lethal COVID-19 in these patients. The study findings suggest that hypogammaglobulinemia and Sars-CoV-2 viraemia are two relevant determinants of COVID-19 severity in this patient population. 

The study team analyzed characteristics of all patients with haematological malignancies admitted to their hospital for COVID-19 from March to November 2020. In total, 51 adult patients with lymphoma, acute leukaemia, myeloma or other types of haematological malignancies were included in the analysis; from those, 24 (47%) had progressed to severe COVID-19. 

Patients who progressed to severe COVID-19 had at hospital admission significantly lower gammaglobulin levels in the serum (p = 0.0312) and tended to have more advanced age (64.7 versus 57.6 years; p = 0.0503). Lymphopenia was not significantly associated with increased risk of developing severe COVID-19. 

By linear logistic regression, hypogammaglobulinemia remained the most significant factor associated with progression to severe COVID-19. The severity of COVID-19 negatively correlated with serum gammaglobulins by the correlation Pearson statistics method (r = -0.43; p = 0.0018). The intensity of viral replication was higher in patients with hypogammaglobulinemia ≤ 6 g/L (p = 0.0033) and duration of virus carrier status in nasopharyngeal swabs tended to be prolonged in patients with severe COVID-19. 

The study team then retrospectively assessed Sars-CoV-2 viraemia in 21 patients by RT-PCR in whole blood and 10 patients had detectable viraemia (42%) at hospital admission. Viraemia was associated with a relative risk of progression to severe COVID-19 (p = 0.0019) and COVID-19 death (p = 0.0351). Furthermore, viraemia was more often present in patients with haematological malignancy as compared with patients with solid tumours (47.6% versus 18.2%; p = 0.0099). 

The authors stated that in patients with haematological malignancies, spread of the SARS-CoV-2 virus related to humoral immunosuppression, rather than cytokine storm, drives the COVID-19 severity. They commented that corticosteroids or anti-cytokines drugs such as anti-IL-6 receptor therapies may worsen immunosuppression and should be used with caution in humoral immunocompromised patients. Therapeutics supporting immunity against Sars-CoV-2, such as hyperimmune convalescent plasma, deserves to be investigated for immunocompromised patients. 

Reference

Michot JM, Hueso T, Ibrahimi N, et al. Severe COVID-19 in patients with hematological cancers presenting with viremia. Annals of Oncology; Published online 12 July 2021. DOI: https://doi.org/10.1016/j.annonc.2021.07.002

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Foodie Friday: It’s Berry Season!

July is National Berry Month! If berries aren’t part of your daily diet, now is the perfect time to start eating more of these...

No Link Between Viral Vector in Zynteglo and Acute Myeloid Leukaemia

On 23 July 2021, the European Medicines Agency (EMA) announced that its Committee for Medicinal Products for Human Use (CHMP) has endorsed findings of...

Expecting Mom Finds Pregnant Stray Cat And Gives Her A Home

A woman was 9 months pregnant when she found a pregnant stray cat. Unable to bear the thought of the fellow mom giving birth...

3 Questions Cancer Caregivers Can Ask Themselves to Help Prevent Burnout

Karen Warner Schueler is the president of her own executive coaching firm and author of The Sudden Caregiver: A Roadmap for Resilient Caregiving. For...

FDA Approval of Rylaze Will Address Drug Shortage for Childhood ALL

July 29, 2021, by NCI Staff FDA's approval of Rylaze is expected to help address a long-running shortage of the drug Erwinia asparaginase for kids...

EMA Recommends Granting a Marketing Authorisation for the Hybrid Medicine Imatinib

On 22 July 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting...